REGN

Regeneron Pharmaceuticals, Inc.

NasdaqGSUSDEQUITY DELAYED

838.10

▲ 11.46 (1.39%)

MARKET · —

Price

Open

826.64

Prev close

826.64

Day high

846.88

Day low

826.64

Volume

717.67K

Market cap

—

P/E (TTM)

—

52W range

541.00 – 847.00

Trailing performance

Price return · vs SPY

Returnvs SPY

+3.80% +5.2%

+27.94% +24.2%

+29.79% +26.7%

+6.97% -4.1%

YTD

+8.05% -4.2%

+41.12% +21.1%

+4.60% -69.6%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

813.02

+3.09% from price

SMA 20

776.69

+7.38% from price

SMA 50

696.27

+19.79% from price

SMA 100

697.55

+20.15% from price

SMA 200

724.45

+15.13% from price

EMA 12

803.50

+4.31% from price

EMA 26

764.09

+9.69% from price

EMA 50

728.96

+14.97% from price

RSI (14)

76.4

Overbought

MACD (12,26,9)

39.41

Hist 2.15

ATR (14)

20.01

2.40% of price

Realised vol 30D

29.6%

Annualised

Bollinger upper

869.35

20, 2σ

Bollinger lower

684.04

20, 2σ

50 / 200 cross

Death

696.27 vs 724.45

Trend bias

Above 200

+15.13%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.48

Less volatile than market

Correlation to SPY

0.18

Largely independent

Realised vol 30D

29.6%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-26.1%

Peak to trough

Max drawdown 5Y

-59.8%

Peak to trough

ATR 14

20.01

2.40% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 838.10

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

REGN · links out to the publisher

Oil Shipper Hits New High; Three Stocks Also Near Pivots Investor's Business Daily · 15h ago How Moderna’s Historic Short Squeeze Upended the AI Chip Trade Barrons.com · 2d ago Regeneron Secures FDA Approval for Rare Genetic Disorder Drug Zacks · 2d ago Regeneron to challenge Ipsen as FDA clears bone disease drug BioPharma Dive · 2d ago Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy Simply Wall St. · 2d ago Regeneron (REGN) Stock Looks Undervalued On Expanded Cancer Collaboration News Simply Wall St. · 2d ago Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline GlobeNewswire · 2d ago Regeneron Announces Investor Conference Presentations GlobeNewswire · 3d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.